Related Experiment Video
Updated: Oct 3, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
Cardiac Manifestations in Patients with COVID-19: A Scoping Review
Sasha Peiris1,2, Pedro Ordunez3, Donald DiPette4
1Incident Management Systems for COVID-19, Pan American Health Organization, Washington, DC, USA.
Insights
COVID-19 frequently impacts the heart, causing cardiac injury, arrhythmias, and acute coronary syndromes, particularly in severe cases. Further research is needed to clarify the role of viral infection versus inflammation and guide treatment.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- Coronavirus disease 2019 (COVID-19) primarily affects the lungs but frequently involves the heart.
- Cardiac manifestations are prevalent in COVID-19 patients, impacting prognosis and outcomes.
- Understanding these cardiac complications is crucial for managing COVID-19 patients.
Purpose of the Study:
- To review the literature on cardiac manifestations in adult COVID-19 patients.
- To summarize the frequency and types of cardiac complications associated with COVID-19.
- To analyze clinical parameters, biomarkers, and pharmacotherapy outcomes related to cardiac involvement in COVID-19.
Main Methods:
- A scoping review of systematic reviews was conducted.
- Databases searched included Embase, PubMed, Epistomonikos, Medrxiv, and BioRxiv up to November 2020.
- Sixty-three systematic reviews were included and their findings extracted.
Main Results:
- Acute cardiac injury occurred in 15%–33% of patients.
- Arrhythmias were more frequent in severe COVID-19 (33.0%–48.0%) compared to non-severe cases (3.1%–6.9%).
- Acute coronary syndromes and myocarditis were also significant complications; Renin-angiotensin-aldosterone system inhibitors (RAASI) showed no association with COVID-19 outcomes.
Conclusions:
- Cardiac injury, arrhythmias, myocarditis, and acute coronary syndrome are significant complications of COVID-19, linked to disease severity and mortality.
- Further research is needed to differentiate between direct viral myocarditis and inflammation-induced cardiac injury.
- Heterogeneous results from systematic reviews highlight the need for randomized trials to establish optimal pharmacotherapy.
Background:
Coronavirus disease 2019 (COVID-19), commonly affects the lungs, but the involvement of other organs, particularly the heart, is highly prevalent as has been reported in several studies. The overall aim of this review was to provide an in-depth description of the available literature related to the cardiac system and COVID-19 infection. It focuses on type and the frequency of cardiac manifestations, clinical parameters and cardiac biomarkers that support the prognosis of COVID-19 patients, and the cardiac adverse events and outcomes related to pharmacotherapy.
Methods:
A scoping review was conducted searching Embase, PubMed, Epistomonikos, Medrxiv, BioRxiv databases, up to November 2020, for systematic reviews relevant to cardiac manifestations in adult COVID-19 patients. Relevant articles were screened and extracted to summarize key outcomes and findings.
Results:
A total of 63 systematic reviews met the inclusion criteria. The overall frequency of acute cardiac injury ranged from 15% to 33% in the reporting studies. The main cardiac complications were arrhythmias (3.1% to 6.9% in non-severe patients, 33.0% to 48.0% in severe disease), acute coronary syndromes (6% to 33% in severe disease), and myocarditis. Most studies found no association with the use of Renin-angiotensin-aldosterone system inhibitors (RAASI) with COVID-19 outcomes such as susceptibility to infection, hospitalization, severity, and mortality.
Conclusion:
This study provided an overview of the several cardiac complications associated with Covid-19. Cardiac injury, arrhythmias, myocarditis, cardiac failure, and acute coronary syndrome, are prevalent and clinically significant and associated with COVID-19 disease severity and mortality. Other studies are needed to clearly identify what is the part of viral heart infection and what is the part of cardiac injury secondary to acute respiratory failure and inflammation. In the therapeutic field, these systematic reviews gave heterogenous results. This underlines the importance of randomized trials to determine the right therapeutic approach.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
08:25Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
Related Concept Videos
Coronary Artery Disease III: Clinical Manifestations
Introduction Cardiac Emergencies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Pericarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies